August 19, 2017 2:48 AM ET

Biotechnology

Company Overview of Acceleron Pharma Inc.

Key Executives for Acceleron Pharma Inc.

NameBoard RelationshipsTitleAge
Habib J. Dable 12 RelationshipsPresident, CEO & Director48
Thomas P. Maniatis Ph.D.28 RelationshipsCo-Founder, Chairman of Scientific Advisory Board and Director74
Mark Ptashne Ph.D.29 RelationshipsCo-Founder and Member of Scientific Advisory Board--
Kevin F. McLaughlin 11 RelationshipsChief Financial Officer, Senior Vice President and Treasurer61
Ravindra Kumar Ph.D.No RelationshipsChief Scientific Officer and Senior Vice President57
View More Key Executives

Acceleron Pharma Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Francois Nader M.D., M.B.A. 30 RelationshipsAcceleron Pharma Inc.60
Habib J. Dable 12 RelationshipsAcceleron Pharma Inc.48
Thomas P. Maniatis Ph.D. 28 RelationshipsAcceleron Pharma Inc.74
Mark Ptashne Ph.D. 29 RelationshipsAcceleron Pharma Inc.--
Jean M. George 56 RelationshipsLightstone Ventures59
View All Board Members

Acceleron Pharma Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Terrence C. Kearney30 Relationships3 Executives
Compensation Committee Joseph S. Zakrzewski76 Relationships3 Executives
Nominating Committee Jean M. George56 Relationships3 Executives
Corporate Governance Committee Jean M. George56 Relationships3 Executives
Advisory Board Ph.D.Thomas P. Maniatis28 Relationships4 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$45.8K
45.8K
387.2K
Bonus$350.0K
350.0K
237.8K
Total Short Term Compensation
Not meaningful
Total Value of Options$395.8K
395.8K
18.6M
Compensation as of Fiscal Year 2016
Acceleron Pharma Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

RHS Limited Appoints Alwin Hui as Chief Commercial Officer
August 18, 2017 3:43 AM ET
Immunocellular Therapeutics, Ltd. Announces Resignation of Mark A. Schlossberg and Gregg A. Lapointe from the Board of Directors
August 17, 2017 8:32 PM ET
Five Prime Therapeutics, Inc. Appoints Bryan Irving as Senior Vice President, Research, with Effect from September 1, 2017
August 17, 2017 8:05 PM ET
BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub; Appoints Michael Scott as Senior Vice President of Product Development and Toronto Operations
August 17, 2017 12:00 PM ET
PsiOxus Therapeutics Announce Two New Board Members
August 17, 2017 7:00 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Acceleron Pharma Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.